Divalproex Sodium Tablet, Extended Release
Product Images NDC 55154-2345

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-2345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (283af6d2 8ea2 4225 B2e7 A2057dbdb793 00)

Divalproex Sodium extended-release tablets, 500 mg strength, oral dosage form. The label includes prescription drug warnings, storage instructions, and dispensing information. It shows a package size of 10 tablets and labelers including Cardinal Health 107, LLC, with manufacturing and distribution details. The NDC 55154-2345 is also displayed.*

FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

Chemical structure diagram of divalproex sodium, showing two valproate anions complexed with a sodium ion. The structure includes branched alkyl chains and carboxylate groups.*

FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

A line graph comparing the percentage reduction in CPS (Complex Partial Seizure) rate between Divalproex Sodium and placebo groups across different percentages of patients. The vertical axis shows percentage reduction in CPS rate, indicating improvement above zero and worsening below zero. The horizontal axis represents the percent of patients from 100 to 0. The graph shows the Divalproex Sodium group exhibits greater improvement compared to placebo over patient percentages.*

FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

A cumulative percentage plot showing the percentage reduction in CPS rate versus the percentage of patients for Divalproex Sodium at high and low doses. The vertical axis represents improvement and worsening in CPS rate, while the horizontal axis indicates patient percentage, with curves comparing high dose (solid line) and low dose (dotted line) effects.*

FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

Bar graph comparing effects of placebo and Divalproex Sodium Extended Release. The graph shows quantitative values on the vertical axis, with placebo represented by a white bar at 0.6 and Divalproex Sodium Extended Release represented by a black bar at 1.2, with a significant p-value of 0.006 noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.